Latest news

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CA IX-Targeted Radiopharmaceutical Program

Iktos announces closing of € 15.5M series A round co-led by M Ventures and Debiopharm

Debiopharm extends their DNA damage repair footprint with new oncology pipeline entry

Challenge pour la Qualité de vie du patient 2023 : l’appel à projets est ouvert !

Debiopharm Applies Extended-Release Formulation Expertise To Reduce Treatment Frequency Burden For Acromegaly & GEP-NET Patients

Le 7e Challenge Qualité de vie du patient récompense le dispositif de massage MRM destiné aux personnes en fauteuil roulant,…

Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial…